Clinical

Articles

Personalized risk assessments that utilize pathogenic variations can help detect CRC early in patients with Lynch Syndrome. 

Personalized Risk Assessments Could Play a Role in Detecting and Treating CRC Plus Lynch Syndrome

Data from a first-of-its-kind study indicated that unnecessary use of antibiotics may lead to early-onset colon cancer.

Unnecessary Use of Antibiotics May Lead to Early Onset CRC in Patients Under 50 Years

Findings from the OCTOPUS Consortium of trial data indicated that weight-based chemotherapy dosing may improve outcomes for obese patients with colorectal cancer.

Weight-Based Chemotherapy Dosing May Improve Outcomes in Obese Populations With CRC

More elderly, frail patients with colorectal cancer were able to complete adjuvant chemotherapy following geriatric intervention.

Geriatric Intervention Increases Rate of Adjuvant Chemotherapy Completion in Older, Frail Populations With CRC

Videos

CancerNetwork® sat down with Marwan G. Fakih, MD, of City of Hope at the 2021 ASCO Annual Meeting to talk about a potential multidisciplinary treatment approach to colorectal cancer with regorafenib/nivolumab.

Marwan G. Fakih, MD, Discusses Regorafenib Plus Nivolumab in CRC and Multidisciplinary Care 

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR/MSI-H Immunotherapy (COMMIT) Study: A Randomized Phase 3 Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination vs Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability–High (MSI-H) Metastatic Colorectal Cancer (NCT02997228).


Clinical Trials in Progress: COMMIT Study

Individuals with an early-onset colorectal cancer diagnosis had a survival benefit versus those at later ages, especially for patients younger than 50 years old. 

Early-Onset Colorectal Study Shows Better Overall Survival for Patients Under 50

The new data may put to rest concerns that adding perioperative systemic therapy might worsen outcomes in patients slated for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Perioperative Systemic Therapy Plus CRS-HIPEC Appears Safe, Feasible in Resectable CPM

In line with responses seen at the primary analysis, final results of a phase 2 trial support activity of trastuzumab deruxtecan in HER2-positive metastatic CRC. 

Consistent Activity of Trastuzumab Deruxtecan Reported for HER2+ mCRC

Adding panitumumab to 5-FU and leucovorin significantly improved PFS compared with 5-FU/leucovorin alone as a maintenance therapy for patients with RAS wild-type metastatic CRC.

Colorectal Cancer | Topics